I have an opportunity to participate in a double blind placebo controlled clinical trial of an anti-PD L1 antibody MEDI4736 as an adjuvant treatment following complete resection (with or without adjuvant chemo) of early stage lung cancer. I am leaning against this for the following reasons but am wondering if these concerns are valid. Certainly I discuss this all with my oncologist soon but maybe this also helps other people decide what to do in their case.
Reasons not to do adjuvant immunotherapy trial
1. No evidence it cures lung cancer but rather controls it for awhile in best cases.
2. Side effects
3. Rebound of cancer growth once trial is over and medication is stopped
4. Acquired resistance to future PD and/or PD L1 immunotherapies if not others
5.Potential exclusion in future clinical trials as a result of having taken this medicine potentially.
6. Only 2/3 chance to actually get the medication
Reasons to do immunotherapy trial
1. Small chance this could put off my disease for long enough until a robust cure is found.
2. Better follow up and surveillance than I can expect to receive otherwise in Canada.
I am wondering if these are reasonable concerns and if I have missed anything.